HER2-low Unresectable and/or Metastatic Breast Cancer in Russia

CompletedOBSERVATIONAL
Enrollment

1,669

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

March 14, 2025

Study Completion Date

March 14, 2025

Conditions
Breast Cancer
Trial Locations (40)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Belgorod

Research Site, Chelyabinsk

Research Site, Chita

Research Site, Grozny

Research Site, Irkutsk

Research Site, Istra

Research Site, Izhevsk

Research Site, Kaluga

Research Site, Kemerovo

Research Site, Khanty-Mansiysk

Research Site, Kirov

Research Site, Kostroma

Research Site, Krasnodar

Research Site, Krasnoyarsk

Research Site, Maykop

Research Site, Moscow

Research Site, Nal'chik

Research Site, Nizhny Novgorod

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Orenburg

Research Site, Perm

Research Site, Pyatigorsk

Research Site, Ryazan

Research Site, Saint Petersburg

Research Site, Saransk

Research Site, Sevedorvinsk

Research Site, Smolensk

Research Site, Sochi

Research Site, Surgut

Research Site, Tomsk

Research Site, Tver'

Research Site, Ufa

Research Site, Ulan-Ude

Research Site, Vladivostok

Research Site, Volgograd

Research Site, Yaroslavl

Research Site, Yuzhno-Sakhalinsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT05913440 - HER2-low Unresectable and/or Metastatic Breast Cancer in Russia | Biotech Hunter | Biotech Hunter